B of A Securities Downgrades Harmony Biosciences to Underperform, Announces $30 Price Target
Portfolio Pulse from Benzinga Newsdesk
B of A Securities analyst Jason Gerberry downgraded Harmony Biosciences (NASDAQ:HRMY) from Neutral to Underperform and set a price target of $30. This suggests a bearish outlook on the company's stock performance.

January 02, 2024 | 12:13 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Harmony Biosciences was downgraded by B of A Securities from Neutral to Underperform with a new price target of $30, indicating a negative sentiment towards the stock's future performance.
Downgrades by analysts can lead to a negative perception among investors and potential selling pressure on the stock. The new price target of $30 set by B of A Securities suggests that the analyst sees downside risk to the current stock price, which could influence short-term price movement negatively.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100